Ascentage Pharma Group International (NASDAQ:AAPG) Upgraded at China Intl Cap

China Intl Cap upgraded shares of Ascentage Pharma Group International (NASDAQ:AAPG) to a strong-buy rating in a research note released on Monday morning,Zacks.com reports.

Several other research firms have also issued reports on AAPG. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Thursday, March 26th. Finally, Rodman & Renshaw started coverage on Ascentage Pharma Group International in a research report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $48.00.

Ascentage Pharma Group International Stock Down 3.2%

AAPG stock opened at $26.47 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. Ascentage Pharma Group International has a 12-month low of $17.56 and a 12-month high of $48.45. The stock’s 50 day simple moving average is $24.03 and its 200 day simple moving average is $29.06.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million during the quarter.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AAPG. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International during the second quarter valued at $391,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at $96,000. ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at $204,000. UBS Group AG increased its holdings in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period. Finally, XY Capital Ltd increased its holdings in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.